Prelude Therapeutics (PRLD) EBITDA (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of EBITDA data on file, last reported at -$14.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 59.03% year-over-year to -$14.2 million; the trailing twelve-month figure through Mar 2026 stood at -$84.1 million (up 39.89% YoY), and the FY2025 full-year result was -$104.6 million, up 25.16% from the prior year.
• EBITDA advanced to -$14.2 million in Q1 2026, from -$17.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$14.2 million in Q1 2026 to a low of -$37.4 million in Q4 2023.
• A 5-year average of -$30.3 million and a median of -$32.4 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 37.88% in 2022 and jumped 59.03% in 2026, its largest moves.
• Tracing PRLD's EBITDA over 5 years: stood at -$33.4 million in 2022, then decreased by 11.96% to -$37.4 million in 2023, then grew by 9.49% to -$33.8 million in 2024, then surged by 48.72% to -$17.3 million in 2025, then climbed by 18.28% to -$14.2 million in 2026.
• Business Quant data shows PRLD's EBITDA at -$14.2 million in Q1 2026, -$17.3 million in Q4 2025, and -$20.4 million in Q3 2025.